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Abstract
Background: The resistance of Ae. aegypti to insecticides is already widespread and continues to develop. It
represents a serious problem for programmes aimed at the control and prevention of dengue in tropical countries.
In the light of this problem measures to control Ae. aegypti are being orientated towards how best to use existing
insecticides, notably by combining those that have different modes of action.
Results: In this study we evaluated the operational efficiency of a mixture composed of pyriproxyfen (an insect
growth regulator) and spinosad (a biopesticide) against a population of Ae. aegypti from Martinique resistant to
pyrethroid and organophosphate insecticides. The first step consisted of evaluating the efficacy of pyriproxyfen and
spinosad when used alone, or in combination, against Ae. aegypti larvae under simulated conditions. The results
showed that the mixture of pyriproxyfen+spinosad remained active for at least 8 months, compared with 3
months for spinosad alone, and 5 months for pyriproxyfen alone. In a second step in containers experiencing
natural conditions, pyriproxyfen and spinosad, maintained the rate of adult emergence at 20% for 3 weeks and 3.5
months, respectively. Following the same criteria of evaluation, the mixture pyriproxyfen+spinosad remained
effective for 4.5 months, showing that the combination of the two larvicides with different modes of action acted
to increase the residual activity of the treatment.
Conclusion: The mixture of pyriproxyfen and spinosad kills larvae and pupae giving it a broader range of action
than either insecticide. This mixture could preserve the utility of both insecticides in public health programs.
Background
Aedes aegypti (L.) is the principle vector of dengue world-
wide, causing 50-100 million cases of infection and 30,000
deaths each year [1]. There is no specific medication or
vaccine available to deal with the arbovirus responsible
and the only means of controlling the disease is to control
its mosquito vectors. The first line of vector control is to
physically eliminate breeding sites where water collects.
However, it is not possible to eliminate all sites and those
that remain need to be treated with efficient and long-last-
ing insecticides active against larvae and/or pupae.
Mosquito control agencies are constrained by the range of
insecticides available to them and would like a broader
range of products that could be used. However the devel-
opment of new families of chemicals acting against novel
targets is rare, requiring years of research in the laboratory
and field. In addition resistance to organophosphates, car-
bamates and pyrethroids in mosquitoes is on the rise and
includes many populations of Ae. aegypti [2-7]. Pyriproxy-
fen (a growth regulator) and spinosad (a biopesticide) have
recently been evaluated for their action against mosqui-
toes. Field and laboratory studies have found pyriproxyfen
(active against the pupal stage) to have good residual activ-
ity against Ae. aegypti [8]. Spinosad (active against larvae)
has been found to have low toxicity for humans and other
non-target fauna [9] and has the potential to be used
against mosquitoes as it does not show cross-resistance
with conventional insecticides [10]. Research into new
strategies aimed at limiting the development of insecticide
* Correspondence: frederic.darriet@ird.fr
1Institut de Recherche pour le Développement (IRD), Laboratoire de Lutte
contre les Insectes Nuisibles, 911 Avenue Agropolis, BP 64501, 34394
Montpellier Cedex 5, France
Full list of author information is available at the end of the article
Darriet et al. Parasites & Vectors 2010, 3:88
http://www.parasitesandvectors.com/content/3/1/88
© 2010 Darriet et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
resistance in mosquitoes has been orientated towards the
use of mixtures of two insecticides, where each one pos-
sesses a different mode of action. In the laboratory, the
association of pyriproxyfen and spinosad has been found
to be synergistic in that it increases the mortality of
Ae. aegypti larvae, thereby also reducing the number of
emerging adults [11].
In this study we investigated the performance of a
mixture of pyriproxyfen and spinosad in field conditions
on the island of Martinique in the French West Indies
against a population of Ae. aegypti resistant to both pyr-
ethroids and organophosphates [7]. The two insecticides
used separately or when mixed together were evaluated
in containers protected from the weather and those
experiencing natural conditions present in the commu-
nity of Vauclin in the south-east of the island. The main
aim was to test the relative efficacy of the pyriproxyfen
and spinosad mixture against that of the two insecticides
when applied individually in two settings calling for
minimal or maximal dosages to be used.
Materials and methods
Mosquito material
The strain of Ae. aegypti used in this study was collected
in the community of Vauclin, Martinique (14°54’N, 60°
84’W) and larvae of the F1 progeny were used for the
simulated trials. This population showed strong resis-
tance to pyrethroid and organophosphate insecticides
due to the presence of a Kdr mutation [f(R) = 0.71;
V1016I] and increased metabolic detoxification (i.e
oxidases, esterases, glutathione S-transferases) [7].
Insecticides
Pyriproxyfen is a juvenile hormone analogue that is par-
ticularly active against pupal stages of development.
It disrupts insect hormonal regulation and results in the
inhibition of development, disturbed behaviour, and an
important decrease in adult fertility [12]. It has low toxi-
city for mammals with an LD50 above 5000 mg/kg for
rats [13]. Spinosad is an insecticide of natural origin
composed of a mixture of two metabolites (spinosins A
and D) produced by the soil bacterium Saccharopoly-
spora spinosa (Actinomycetes). Its mode of action is
unique as it acts against both GABA and nicotinic
receptors in the insect nervous system [14]. It
has low toxicity for mammals with an LD50 of 3783 -
5000 mg/kg for rats [13].
Simulated field trial
A phase II trial was conducted at Fort-de-France (Marti-
nique) following the standard procedures of the World
Health Organisation (WHO) [15]. The efficacy and resi-
dual activity of pyriproxyfen [Sumilarv®, granules (GR)
0.5%] and of spinosad [granules (GR) 0.5%] used alone
or in combination were measured in plastic containers
of a type that represents the most productive larval
breeding sites of Ae. aegypti in Martinique [16]. The
175 litre containers were filled with 145 litres of tap
water and then covered with mosquito nets held in
place by a metal clamp to prevent oviposition by wild
female mosquitoes from the area (Figure 1). These con-
tainers were placed undercover where they were pro-
tected from the sun and rain. The trial involved a total
of 12 containers, where 3 were treated with pyriproxyfen
(0.02 mg/l), 3 with spinosad (0.1 mg/l), 3 with a mixture
of pyriproxyfen and spinosad (0.02 mg/l + 0.1 mg/l),
and 3 were untreated and served as controls. The doses
of 0.02 mg/l of pyriproxyfen and 0.1 mg/l of spinosad
represent the minimal doses recommended by the
WHO for the control of Ae. aegypti larvae [17,18]. At
the moment of treatment, and every 10 days thereafter
for the rest of the trial, 100 third instar Ae. aegypti lar-
vae of the Vauclin strain (F1 progeny) were added to
each container and their survival was followed until
adult emergence. Each time larvae were added to a con-
tainer, the container was refilled with water to maintain
a constant volume against water lost due to evaporation
(~200-300 ml every 10 days) and 1 g of ground cat food
biscuits was added to provide food for the larvae.
Trials in natural breeding sites
The trials were conducted from February to August
2008 in the community of Vauclin, situated in the
south-east of Martinique on the Atlantic coast. Three
isolated sites were chosen at least 2 km from one
another, to avoid possible migration of mosquitoes
between locations; Anse Maroquet (14°33’N, 60°49’W),
Château Paille (14°33’N, 60°50’W) and Cadette (14°33’N,
60°52’W). Anse Maroquet is a fishing village situated in
a bay, Château Paille is a housing development, and
Cadette a collection of houses situated approximately
4 km further inland. This region of the island has a
Figure 1 Plastic 175 litre containers used in the trial of
larvicides against Ae. aegypti in simulated field trial.
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humid tropical climate with rainy season running from
May to September with an annual precipitation of
~2000 mm. In each locality, 20 containers (100-200
litres capacity) positive in Ae. aegypti larvae were chosen
for the trials, i.e., 5 containers for each of the 3 insecti-
cide treatments and 5 for the untreated control
(Figure 2). The quantity of insecticide added to contain-
ers was calculated as a function of their holding capacity
without taking into account the volume of water pre-
sent; this was not controlled and varied during the
course of the trial. The formulation of pyriproxyfen
used was the same as that used in the simulated trials
involving the protected containers (GR 0.5%). For spino-
sad, the formulation used was in the form of a direct
application tablet (DT 7.48%). The concentration of 0.05
mg/l of pyriproxyfen and the equivalent of 1 spinosad
tablet for 200 litres of water (= 0.5 mg/l) represent the
maximum doses recommended by the WHO [17,18].
The concentration of the mixture involved a total of
0.05 mg/l of pyriproxyfen and 0.5 mg/l of spinosad. The
allocation of treatments to containers within each site
was done at random, with 5 containers receiving the
same treatment in each site. The density of larvae and
pupae in each container was evaluated prior to treat-
ment and 2 days following treatment (D0 and D2), and
then once a week thereafter (D7, D14, D21, D28, D35,...).
The sampling method was based on 3 dips with a small
fish net and by counting the number of 3rd and 4th
instar larvae, as well as the number of pupae. First, 2nd
and 3rd instar larvae were replaced in their respective
containers, while 4th instar larvae and pupae were
brought back to the laboratory in 200 ml of water from
the same container to estimate adult emergence. Each
treated container was followed in the field until the rela-
tive density of larvae was > 20% of its initial density (D0
= 100%) and the percentage emergence of adults was
≥ 20% (equivalent to ≤ 80% inhibition of emergence)
[15]. The sampling of some containers was abandoned
during the course of the trial in cases where they were
completely emptied (e.g. due to domestic use) or
disappeared.
Statistical analyses
The data collected from the trials in the artificial and
natural containers were analysed separately using a
split-plot design for the analyses of variance (ANOVA)
with repeated measures for the different times of sam-
pling (see below for details).
In the simulated field trial, the time (in days) required
for the inhibition of adult emergence (%IE) to pass
below the threshold value of 80% was estimated for
each treatment according to the formula [15]:
%IE C TC= ×
− 100 where C represents the average per-
centage emergence in the untreated (control) containers
at a particular time and T represents the average per-
centage emergence in the treated containers in the same
period.
For the trial involving containers in natural conditions,
calculations were based on the relative density (RD) of
3rd and 4th instar larvae and pupae in each container,
for each location, day of sampling and insecticide treat-
ment. This analysis did not directly test variation in the
density of control larvae, but data from control contain-
ers were incorporated in the estimation of RD according
to the following equation: %RD CT
T
C
= ( ) ( ) ×11 22 100 where
C1 is the average number of 3rd/4th instar larvae and
pupae in the 5 control (untreated) containers in a parti-
cular site at time D0; T1 is the average number of 3rd/
4th instar larvae and pupae in the 5 treated containers
of a particular treatment and site at time D0; C2 is the
average number of 3rd/4th instar larvae and pupae in
the 5 control containers of a particular site and day of
sampling, and T2 is the number of 3rd/4th instar larvae
and pupae in each treated container of the insecticide
treatments, per site and day of sampling. Relative densi-
ties were analysed until D140, as after that date, the
number of containers yielding data was insufficient for
analysis. In the laboratory, percentage adult emergence
was calculated using the formula: %E C TC= − ( ) ×−100 100
where C and T were as above for the containers in pro-
tected conditions. A split-plot ANOVA was used to ana-
lyse the inhibition of emergence (%IE) and relative
density (%RD) of mosquitoes in containers exposed to
natural variation. The whole plot level of the design
involved the three locations (treated as a nominal
Figure 2 Containers of Ae. aegypti exposed to natural variation
from the site “Cadette” used in the study. The three largest
containers were treated.
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random effect), and the three insecticide treatments
(treated as a nominal fixed effect). The error term for
the whole plot involved the interaction between the fac-
tors location and treatment. The model also included a
term for container within location and treatment to
account for random variation among replicate contain-
ers. The sub-plot level of the model involved the factor
‘day of sampling’ as a nominal fixed effect and the inter-
action between day and treatment; these were tested
against the remaining residual error variation.
Percentage data were logit transformed (log [%x/(1 - %
x)]) for analyses to standard errors within the bounds of
0 - 100% when back-transformed to the percentage scale.
In the analysis of %RD, the estimates of average values
(e.g. the average number of control larvae in replicate
containers from a particular site at time zero) were calcu-
lated on the scale of log (x + 1) to help stabilise estimates
and back-transformed. Calculations leading to negative
estimates of %RD were set to zero. The percentage data
were scaled to values between 0 and 1 using the formula;
0.05 + 0.99x prior to logit transformation. Models were
analysed using the Restricted Maximum Likelihood
method (REML) of JMP® version 7.0.1 [19].
Results
Simulated field trials
The results of this trial for the containers treated with
insecticides are presented in Figure 3. The rate of emer-
gence inhibition for adult Ae. aegypti fell below the
threshold value of 80% after 110 days (~3.5 months) for
spinosad and after 160 days (~5.3 months) for pyriprox-
yfen. Following the same criteria, the activity of the mix-
ture of pyriproxyfen+spinosad lasted for at least
250 days (~8 months), that is, 1.6 - 2.0 times longer
than for spinosad and pyriproxyfen when each was used
alone. Mortality in the control containers (not shown)
generally did not go above 10%, except in sampling peri-
ods 1 (10 days), 5 (50 days) and 11 (110 days) where
mortality was > 20%.
Trials in natural breeding sites
The factor location (Anse Maroquet, Château Paille,
Cadette) and its interaction with different treatments
had little influence on the results of these trials as the
coefficients of variance accounted for <1% and ~5% of
variance explained by the ANOVA models for relative
density and inhibition of emergence (Table 1). A greater
proportion of the variation in the data could be attribu-
ted to variation among containers within a particular
treatment and location (Table 1). The density of larvae/
pupae in the control containers varied over the course
of the trial, decreasing relative to its initial value and
then increasing again after ~70 days (Figure 4). Calcula-
tions for the relative density of larvae/pupae in the trea-
ted containers take this variation into account. There
was no consistent pattern in the relative density of
larvae/pupae exposed to pyriproxyfen which fluctuated
considerable over the course of the trial (Figure 4).
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Figure 3 Simulated field trial. Residual activity of pyriproxyfen and spinosad when used alone or as a mixture on the inhibition of emergence
for Ae. aegypti (± s.e.).
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However it is difficult to estimate the efficiency of this
insecticide in the field based on larval counts as many
of the observed larvae, though still alive, would not have
completed their development to the adult stage. For spi-
nosad, the relative density of pre-adults passed the 20%
threshold and regained 45% of their initial numbers 105
days after treatment (~3.5 months). With the mixture of
pyriproxyfen+spinosad, the relative density of pre-adults
rebounded to 30% of its initial value after 112 days, but
then fell again to below 20% in the subsequent samples
until D140 (~4.5 months)(Figure 4). Data from larvae
and pupae brought back to the laboratory allowed calcu-
lation of the 20% threshold for adult emergence (or 80%
inhibition of emergence) beyond which it is recom-
mended to treat again. This threshold was reached after
21 days for pyriproxyfen, 105 days for spinosad, and 133
days for the mixture of pyriproxyfen+spinosad (Figure
5). It was interesting to note the dramatic drop in the
efficacy of pyriproxyfen between days 21-28. We cannot
currently explain this observation but think it merits
attention in future studies. In the containers treated
with spinosad and the mixture of the two larvicides, it
was interesting to note that the time needed for pre-
adult populations to recover 20% of their initial size
coincided with the time necessary for adult emergence
to reach 20% in laboratory conditions.
Discussion
Ecological considerations are increasingly important and
strategies of mosquito control must give priority to
insecticides that are effective and respect the environ-
ment. Correspondingly, a tightening of European direc-
tives (Directive Biocide 98/8), has tended to exclude
compounds from the families of organochlorides, orga-
nophosphates and carbamates from use in public health
programs. Mosquito control agencies in Europe now
often have no other alternative than to use the biopesti-
cide Bacillus thuringiensis var israelensis (Bti) [20].
Table 1 Split-plot repeated measures analysis of variance
for treatment effects on Ae. aegypti in the field
experiments
Source N DFnum DFden F P CV
Relative Density
Treatment (T) 3 2 3.9 9.8 0.03 -
Day (D) 21 20 516.8 10.8 < 0.001 -
DxT 110 84 516.5 0.9 0.5 -
Locality (L) 3 - - - - < 1%
LxT 15 - - - - 4.61%
Container (C) [LxT] 45 - - - - 7.3%
Emergence inhibition
Treatment (T) 3 2 503 16.8 < 0.001 -
Day (D) 22 21 503 12.8 < 0.001 -
DxT 66 42 503 1.5 0.03 -
Locality (L) 3 - - - - < 1%
LxT 9 - - - - 5.3%
Container (C) [LxT] 45 - - - - 24%
N = number of parameters,
DFnum = degrees of freedom numerator,
DFden = degrees of freedom denominator,
CV = coefficient of variance.
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Figure 4 Trial in natural breeding sites. Relative density (RD) of third and fourth instars larvae and pupae of Ae. aegypti before and after
treating containers with pyriproxyfen, spinosad and their mixture (± s.e.).
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If suspected cases of resistance to Bti in Culex pipiens
from New York [21] are excluded, there are no cases of
mosquito resistance to Bti as the different toxins in its
parasporal crystals act in synergy [22]. Resistance to spi-
nosad has not been reported for mosquitoes. The Vau-
clin strain of Ae. aegypti, which is already resistant to
pyrethroid and organophosphate insecticides, shows a
decreased susceptibility to pyriproxyfen with a signifi-
cant resistance ratio (RR50 = 2) relative to the suscepti-
ble Bora strain [23]. This difference in susceptibility
could be explained by the different genetic backgrounds
of the two strains and/or due to the over expression of
the numerous detoxifying enzymes responsible for the
pyrethroids and organophosphates resistance, hence
conferring a “cross tolerance” to pyriproxyfen. In Brazil
it has already been found that some populations of
Ae. aegypti resistant to temephos have cross-resistance
to a juvenile hormone analogue, methoprene [24]. Insec-
ticides cause strong selection pressures on their target
populations, and their prolonged use often leads to the
evolution of resistance to the compound concerned and
those with the same or similar modes of action. The use
of a mixture composed of two insecticides with different
modes of action acting on different targets diminishes
the short-term risk that resistance will arise to one or
the other of the active compounds [25]. In the case of
the association between pyriproxyfen and spinosad, the
efficacy of the first against the pupal stage combines
with that of the second, which acts more specifically
against larvae. This complementary action translates
into a powerful synergistic effect at concentrations close
to the LC99 [11].
In the containers protected from the sun and weather,
the mixture of pyriproxyfen+spinosad remained active
for at least 8 months against the Vauclin strain of
Ae. aegypti in comparison to 3.5 months and 5 months
for spinosad and pyriproxyfen, respectively, when applied
alone. When the treated waters were in containers
protected from sunlight and bad weather, the two larvi-
cides alone and when mixed were remarkably stable. In
contrast in the containers exposed to natural variation,
pyriproxyfen was only effective for 21 days. Following the
same criteria, spinosad remained active for 3.5 months
and the mixture for 4.5 months. At doses comprised
between 0.02 and 0.05 mg/l, the WHO estimate 1 month
of activity for pyriproxyfen [17]. With a residual activity
of 3.5 months in the natural containers, spinosad (= 0.5
mg/l) was shown to be a promising candidate for the
control of Ae. aegypti. The WHO estimates its activity to
be 2 - 3 times less at dose of 0.1 and 0.5 mg/l [18]. The
mixture of pyriproxyfen+spinosad had advantages that
neither of the two insecticides had when used alone. In
particular the rapid action of spinosad on larvae comple-
ments the action of pyriproxyfen and leads to the rapid
mortality of both larvae and pupae in a site. This provides
a strong practical advantage as the effects of treatment
can be rapidly assessed by health workers directly in the
field. In contrast, treatments involving insect growth reg-
ulators, such as ecdysteroids (diflubenzuron, triflumuron,
novaluron, teflubenzuron, etc...) or juvenile hormones
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(methoprene, fenoxycarb, pyriproxyfen), take longer to
act and do not kill all the individuals present in a site.
This is not to say such treatments are not efficient in
reducing adult numbers. What it does mean, however, is
that laboratory bioassays are often required to verify if
any remaining larvae or pupae will contribute to the
adult population or not. This will necessarily add to the
costs of control in terms of both time and money, com-
pared with treatments where both larvae and pupae are
rapidly killed.
Insecticides that work in synergy when mixed together
are an avenue to explore in mosquito control for the
needs of public health. Negative aspects of such combi-
nations are those shared with conventional insecticides,
in that resistance is ultimately expected to evolve in
response to prolonged use and that it is not possible to
clearly predict how efficient mixtures will remain if
resistance to one of the compounds already exists or
develops. Nonetheless, combinations of insecticides with
different modes of action could make an efficient contri-
bution in the fight against mosquitoes, notably in
regions where mosquitoes already show high levels of
resistance to conventional insecticides. The availability
of new families of insecticides has been scarce in the
last 10 years and relying on the appearance of new pro-
ducts is not a realistic option for the control of resistant
populations in the short- to medium-term future. In
contrast, the option of associating insecticides with dif-
ferent modes of action is available now. This is a con-
cept currently too often overlooked in public health,
although in agricultural practice mixtures of insecticides
have been used for more than 20 years [26,27].
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